Patients from 22+ countriesPlan your visit →
lutetium-therapy
Considering Lu-177 Therapy · 18 Jul 2026

Lu-177 PSMA When Multiple Hormone Therapies Have Failed

If you have already tried abiraterone, enzalutamide, or apalutamide for mCRPC, the number of hormone therapies you have taken does not close the door on Lu-177 PSMA. What matters most is whether your tumors are still PSMA-positive on a PET scan.

Editorial oversight by Arpan Talwar·Founder, Art of Healing CancerUpdated 18 Jul 2026
Lu-177 PSMA When Multiple Hormone Therapies Have Failed

Having tried abiraterone, enzalutamide, or apalutamide does not rule out Lu-177 PSMA therapy. This article is for men with metastatic castration-resistant prostate cancer (mCRPC). Eligibility depends on one question: whether your tumors still express the PSMA protein on a PET scan, not how many prior hormone drugs you have taken.

Your treatment history matters for sequencing decisions, but it won't stop you from getting Lu-177 PSMA. Many men who have tried two or three ARPIs still have PSMA-positive tumors. A theranostics team looks at your PSMA PET scan first, not how many treatments you've had.

Why hormone therapies eventually stop working in mCRPC

Metastatic castration-resistant prostate cancer has spread to other parts of the body and keeps growing even when testosterone levels are very low. The cancer can develop changes - sometimes called androgen receptor mutations or splice variants - that let it bypass the signals these drugs were designed to block.

Abiraterone (brand name Zytiga), enzalutamide (Xtandi), and apalutamide (Erleada) all belong to a family called androgen receptor pathway inhibitors (ARPIs). They each attack the same signaling pathway from a slightly different angle, which is why some doctors try a second ARPI after the first stops working. Over time, however, the cancer may learn to bypass the androgen receptor pathway entirely. When that happens, further ARPI switches within the same drug family tend not to help.

Lu-177 PSMA therapy - formally called lutetium Lu-177 vipivotide tetraxetan - takes a fundamentally different route. It does not target hormones or their receptors. Instead, it targets a protein called prostate-specific membrane antigen (PSMA) that sits on the surface of most prostate cancer cells. A radioactive molecule attached to a PSMA-targeting agent is carried to those cells and releases focused radiation directly at the tumor sites. For a fuller explanation of how this works, see our guide on how Lu-177 PSMA works and what theranostics means for metastatic prostate cancer.

What the FDA approvals actually require

Lutetium Lu-177 vipivotide tetraxetan (Pluvicto) has two US approvals, covering two different groups of mCRPC patients. The first approval came in March 2022, based on the VISION trial. The second, expanded approval came in March 2025, based on the PSMAfore trial. Both pathways share one firm requirement: a positive PSMA PET scan.

Neither approval sets a limit on the number of ARPIs you have tried before seeking Lu-177 PSMA. You need to have received ARPI therapy, but it doesn't have to be your first or only hormone treatment.

How do the two approved Lu-177 PSMA eligibility pathways compare?

Lu-177 PSMA eligibility: 2022 post-taxane approval vs 2025 pre-taxane expansion for mCRPC
Eligibility factorPost-taxane pathway (2022 approval)Pre-taxane pathway (2025 expansion)
Prior ARPI required?Yes - at least one (e.g., abiraterone, enzalutamide)Yes - at least one ARPI required
Prior taxane required?Yes - at least one taxane (e.g., docetaxel)No - approved before taxane chemotherapy
PSMA PET scanMust be positiveMust be positive
Key clinical trialVISION trial (831 patients)PSMAfore trial (468 patients)
Typical patient profileHas had both ARPI and docetaxel; disease still growingHas had ARPI; wants to delay or avoid chemotherapy

Sources: Lutetium Lu 177 Vipivotide Tetraxetan first approval summary, PMC 2022; FDA expanded approval announcement, March 2025.

Both pathways require prior ARPI therapy but differ entirely on chemotherapy history. If you have tried abiraterone and then enzalutamide - or added apalutamide - and your cancer has continued to grow, but you have not yet had taxane chemotherapy such as docetaxel, the 2025 expansion offers a route to Lu-177 PSMA without requiring chemotherapy first. That expansion was designed specifically for men in this position: ARPI-experienced, chemo-naive, and PSMA-positive.

What the VISION trial found - and what it required

The VISION trial is the foundational evidence behind the 2022 approval. It enrolled 831 men with PSMA-positive mCRPC who had each received at least one ARPI and between one and two taxane regimens. Results showed that Lu-177 PSMA, added to best supportive care, was associated with a median overall survival of 15.3 months compared with 11.3 months for best supportive care alone, with a hazard ratio of 0.62. Radiographic progression-free survival was 8.7 months for the Lu-177 group versus 3.4 months for standard care.

The VISION trial did not restrict patients based on the number of prior ARPIs. Whether a participant had taken one or two ARPIs before enrolling, the key entry requirement was PSMA-positive imaging and confirmed disease progression. Trying abiraterone and then enzalutamide - and finding both no longer effective - meets the ARPI requirement. What mattered for eligibility was your PSMA scan result, not how many drugs you'd tried.

The PSMA PET scan: the eligibility question that actually matters

Your eligibility for Lu-177 PSMA depends on what your PSMA PET scan shows, not on how many hormone drugs you've tried. The scan uses a small radioactive tracer, typically gallium-68 PSMA-11 (Locametz) or fluorine-18 DCFPyL (Pylarify), to show where cancer has spread in the body and whether those lesions carry enough PSMA to be a target for the therapy.

In the VISION trial, eligibility required at least one metastatic lesion with PSMA uptake greater than the background uptake seen in the liver. That threshold - at least one lesion brighter than the liver on the scan - is still used as a standard for checking eligibility. The Prostate Cancer Foundation notes that PSMA PET imaging is the central tool for patient selection across both approved indications.

Why is this reassuring after multiple ARPI failures? Because ARPIs work on the androgen receptor pathway - an entirely different molecular mechanism from PSMA expression. Failing two or three ARPIs does not reduce the amount of PSMA protein on your cancer cells. Many men who have progressed through multiple ARPIs still have strongly PSMA-positive disease and may be good candidates for Lu-177 PSMA based on their scan result alone.

That said, a small proportion of mCRPC tumors do lose or reduce PSMA expression over time - particularly tumors that undergo a transformation called neuroendocrine differentiation, which doctors see in some cases of heavily treated advanced disease. This is not a direct consequence of ARPI use, but it can develop as the cancer evolves over years of treatment. A fresh PSMA PET scan, done at the time of eligibility review instead of using older images, gives the most accurate picture of your current PSMA status. Our article on what blood tests and scans you need before Lu-177 PSMA treatment walks through the full pre-treatment assessment.

What can actually disqualify you after multiple hormone failures?

The factors that may make Lu-177 PSMA unsuitable are generally not connected to how many ARPIs you have tried. They relate to your current tumor biology, organ function, and overall fitness:

  • PSMA-negative or very low PSMA disease. If the scan shows that your tumor lesions don't take up enough of the PSMA tracer, the therapy has no reliable target to reach. This is the most common reason an mCRPC patient is not offered Lu-177 PSMA.
  • Significant PSMA-negative disease on other scans. If a CT or bone scan shows large lesions that don't appear on the PSMA PET, those lesions likely lack PSMA. Treating only the PSMA-positive sites while PSMA-negative lesions continue to grow is not a complete solution.
  • Significantly impaired kidney function. Lu-177 PSMA passes through your kidneys. If kidney function is already substantially reduced, the full treatment course may not be safe to complete.
  • Very low blood counts before treatment starts. Low red blood cell, white blood cell, or platelet counts before treatment suggest limited bone marrow reserve, which may increase the risk of complications during therapy.
  • Very poor performance status. Patients need to be well enough to receive infusions, travel to the treatment center, and attend the follow-up visits that each cycle requires. Clinical teams use the ECOG performance scale (0 to 2) to check how well you are for treatment.

None of these factors are automatic consequences of having tried three ARPIs. They depend on your current scans, blood work, kidney function, and day-to-day health, not on what drugs you've taken.

Where does chemotherapy fit when multiple ARPIs have failed?

If you have progressed through multiple ARPIs and have not yet had taxane chemotherapy, you may face a choice: try docetaxel next, or explore Lu-177 PSMA first. The 2025 FDA expansion settled the regulatory question by formally approving Lu-177 PSMA before taxane chemotherapy for eligible patients.

That approval keeps chemotherapy as an option later. Some men receive Lu-177 PSMA first and, if disease progresses again later, may still be considered for docetaxel. The sequence is no longer fixed by the approval pathways. For a detailed look at how Lu-177 PSMA fits in the post-docetaxel setting - when chemotherapy has already been part of your history - our guide on Lu-177 PSMA eligibility and sequencing after docetaxel in mCRPC covers that specific situation.

Your oncology team, working alongside a nuclear-medicine or theranostics specialist, can help you decide the order of treatments based on your current scan findings, disease burden, and overall health.

How to take the next step

If your cancer has progressed through multiple ARPIs and you want to find out whether Lu-177 PSMA is an option, the practical first step is arranging a PSMA PET scan. Your medical oncologist or urologic oncologist can order this. The scan is available at academic medical centers and nuclear-medicine departments in many countries, including India, where international patients often access it as part of a coordinated eligibility review at a substantially lower cost than in the US, UK, or GCC countries.

Once your scan is available, a theranostics team looks at your full situation: the PSMA PET result, current blood counts, kidney function, treatment history, and performance status. This review is what matters for deciding if Lu-177 PSMA is an option for you now.

If you want an independent assessment before committing to a center or a plan, you can request a Lu-177 eligibility review through Art of Healing Cancer. The nuclear-medicine team can assess your PSMA-PET report and full treatment history and advise whether Lu-177 PSMA fits your current situation - or what alternatives may be appropriate if it does not.

To send your PSMA-PET scans or request a teleconsultation on eligibility, use the Lutetium Therapy contact form. If Lu-177 PSMA isn't the right choice now, the team can help you understand what other pathways may apply to your case.

When to talk to your doctor

Talk to your oncology team if your PSA is rising on your current hormone drug, or if your most recent imaging shows new or enlarging lesions. Ask whether a PSMA PET scan and a theranostics or nuclear-medicine consultation are appropriate at this stage. If your doctor hasn't mentioned Lu-177 PSMA and your disease is progressing, asking directly - or seeking an independent eligibility review - is a reasonable next step.

This article is for general educational purposes and is not a substitute for personalised medical advice from a qualified oncologist. Always consult your oncologist or care team about your specific situation.

Frequently asked questions

Does failing abiraterone, enzalutamide, and apalutamide mean I have no chance of qualifying for Lu-177 PSMA?

No. The number of ARPIs you have tried does not determine your eligibility for Lu-177 PSMA. Both the original 2022 FDA approval and the 2025 expanded approval require only that you have received at least one ARPI - not that it must have been your only hormone drug. What opens or closes the door is your PSMA PET scan result. If your tumors still express enough PSMA protein to show up brightly on the scan, the therapy may still apply to you regardless of how many ARPIs you have been through.

Do I need to have had chemotherapy before I can receive Lu-177 PSMA?

Not necessarily. In March 2025 the FDA expanded approval of lutetium Lu-177 vipivotide tetraxetan to include mCRPC patients who have had at least one ARPI but have not yet received taxane chemotherapy, based on the PSMAfore trial. If you have failed multiple ARPIs but have not had docetaxel, you may now qualify for Lu-177 PSMA without needing chemotherapy first. Your doctor can help assess whether the expanded eligibility criteria apply to your situation.

Can abiraterone or enzalutamide cause my tumors to lose PSMA expression?

Not directly. ARPIs work on the androgen receptor pathway and do not cause PSMA protein to disappear from cancer cells. However, in some cases of very advanced mCRPC, the tumor can undergo a biological shift called neuroendocrine differentiation, which can reduce or eliminate PSMA expression. This is not a side effect of ARPIs specifically - it is a disease evolution pattern that can occur in heavily pre-treated prostate cancer. A fresh PSMA PET scan at the time of eligibility review is therefore more informative than older imaging done months earlier.

What does it mean if my PSMA PET scan comes back negative after multiple hormone therapy failures?

A negative PSMA PET scan means your tumor lesions are not expressing enough PSMA protein to be reliably targeted by Lu-177 PSMA therapy. It does not mean all treatment options are exhausted. Your team may consider taxane chemotherapy if you have not had it, PARP inhibitor therapy if you carry relevant gene mutations such as BRCA2, clinical trials, or other systemic options. A specialist second opinion can help confirm whether the scan result has been interpreted correctly and what next steps are available.

Is Lu-177 PSMA available for international patients who have failed multiple ARPIs?

Yes. Several countries - including India - have established nuclear-medicine and theranostics centers that offer lutetium Lu-177 vipivotide tetraxetan to international patients. Eligibility is assessed the same way regardless of where treatment is received: the PSMA PET scan result, blood counts, kidney function, and performance status are all reviewed. International patients often choose India because the treatment is available at a cost significantly lower than in the US, UK, or GCC countries, and a coordinated eligibility review and treatment plan can be arranged in advance of travel.

What is the difference between the VISION trial criteria and the current FDA-approved label for Lu-177 PSMA?

The VISION trial enrolled men who had received both at least one ARPI and at least one taxane regimen. The original 2022 FDA approval reflected those criteria. The current label now includes both that original population and an expanded 2025 group - men who have received at least one ARPI and are considered appropriate to delay taxane chemotherapy. The PSMA PET positivity requirement applies to both groups. Your oncologist and nuclear-medicine team will review your specific history to determine which pathway applies to you.

Have a specific question about your situation?

A free conversation with a patient navigator can help you understand whether Lutetium therapy fits your case, what questions to ask your oncologist, and which centers might be right for you.

Navigators don't diagnose or prescribe. They help you have better conversations with the doctors who do.